Cullinan Oncology

Cullinan Oncology is a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients.

Cullinan Oncology's goal is to develop therapeutics that will dramatically improve the standard-of-care for those with cancer.

Cullinan Oncology was founded in 2016 and is headquartered in Cambridge, Massachusetts.

 

Cullinan Management combines a unique portfolio model with innovative sourcing techniques and drug development expertise to discover and advance candidates for potentially transformative oncology drugs.

 

Cullinan leverages a wide range of relationships across the development spectrum to create, identify and develop promising science. The company's internally-driven idea creation complements their externally-focused business development activities as they look to create a portfolio of uncorrelated oncology assets.

 

Cullinan is backed by Foresite Capital, MPM Capital, F2 Ventures, Cowen Healthcare Investments, Boxer Capital of Tavistock Group, Eventide Asset Management and others. The company raised $131.2M in Series C round on Dec 17, 2020. This brings Cullinan's total funding to $379.7M to date. The company went public on Jan 07, 2021 and raised $249.9M from the listing.

 

 

  • Year founded: 2016
  • Funding Info: $379.7M over 3 Rounds (Latest Funding Type: Series C)
  • Yearly Revenue: NA
  • Employee Size: 11-50
  • Business Valuation: NA
  • City/Town: Cambridge
  • State: Massachusetts
  • Country: United States
Related businesses